Status:

COMPLETED

Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

Lead Sponsor:

Université de Sherbrooke

Collaborating Sponsors:

Association Pulmonaire du Quebec

Réseau de Recherche en Santé Respiratoire du Québec

Conditions:

Asthma

Asthma in Children

Eligibility:

All Genders

18+ years

Brief Summary

Asthma is characterised by episodic symptoms (attacks) caused by airway inflammation and decreased airflow to the lungs. It affects 10% of the Canadian population and is the most common chronic diseas...

Detailed Description

BACKGROUND Asthma affects 10% of the general population but remains a diagnostic challenge. Considering the difficult access, weak specificity, and low clinical utility of bronchial provocation tests,...

Eligibility Criteria

Inclusion

  • aged ≥ 12 years who have symptoms suggestive of asthma,
  • referred by their primary care provider (defined as a non-respirologist, non-allergist, non-otolaryngologist) using the CHUS suspected asthma decision-making algorithm. Under that algorithm, patients have non-diagnostic pre- and post-bronchodilator spirometry and no contraindications to a methacholine challenge.
  • Free and informed consent must be given by the patient (and their legal guardian, if applicable).

Exclusion

  • Use of an inhaled or systemic corticosteroid in the previous 48 hours;
  • Smoking in the previous 6 hours; history of viral and/or bacterial respiratory infection in the past 4 weeks;
  • major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged ≥ 40 years , ii) permanent obstruction on spirometry (FEV1/FVC \<0.7) and iii) a smoking history of \>10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.

Key Trial Info

Start Date :

November 7 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 31 2025

Estimated Enrollment :

123 Patients enrolled

Trial Details

Trial ID

NCT05992519

Start Date

November 7 2022

End Date

October 31 2025

Last Update

November 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre de Recherche du CHUS

Sherbrooke, Quebec, Canada, J1H5N4